Showcases Stock ranks Forex

Iteos Therapeutics Inc (ITOS)
14.24  -0.87 (-5.76%) 06-09 16:00
Open: 15.19 Pre. Close: 15.11
High: 15.2 Low: 14.15
Volume: 201,625 Market Cap: 509(M)
Stock Technical Analysis
Target: Six months: 19.32
One year: 21.30
Support: Support1: 13.80
Support2: 11.48
Resistance: Resistance1: 16.54
Resistance2: 18.24
Pivot: 15.47
Moving Averages: MA(5): 15.08
MA(20): 15.30
MA(100): 16.17
MA(250): 19.05
MACD: MACD(12,26): 0.18
Signal(12,26,9): 0.33
%K %D: %K(14,3): 24.94
%D(3): 30.43
RSI: RSI(14): 44.42
52-Week: High: 28.05
Low: 12.52
Change(%): -19.8
Average Vol(K): 3-Month: 266
10-Days: 373
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 15.229 - 15.316 15.316 - 15.41
Low: 13.919 - 14.01 14.01 - 14.109
Close: 14.068 - 14.227 14.227 - 14.399
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ ITOS ] has closed above bottom band by 17.4%. Bollinger Bands are 20.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Stock chart
Stock News
Thu, 08 Jun 2023
New Drugs in Fight Against Cancer Being Powered by Novel ... - PR Newswire

Wed, 07 Jun 2023
AXL Inhibitors Clinical Trial Pipeline Insights Featuring 16+ ... - InvestorsObserver

Wed, 07 Jun 2023
Validea's Top 5 Health Care Stocks Based On Warren Buffett - 6/7 ... - Nasdaq

Wed, 07 Jun 2023
UBS Group AG Acquires 23027 Shares of iTeos Therapeutics, Inc ... - MarketBeat

Wed, 31 May 2023
Can iTeos Therapeutics Inc (ITOS) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver

Fri, 26 May 2023
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday’s Mid-Day Session - A - Benzinga

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 35.76
Shares Float (M) 24.52
% Held by Insiders 0.26
% Held by Institutions 105.22
Shares Short (K) 1780
Shares Short Prior Month (K) 1720
Stock Financials
EPS 0.290
Book Value (p.s.) 18.240
Profit Margin 9.02
Operating Margin -14.22
Return on Assets (ttm) -1.4
Return on Equity (ttm) 1.8
Qtrly Rev. Growth -91.7
Gross Profit (p.s.) 7.484
Sales Per Share 3.571
EBITDA (p.s.) -0.484
Qtrly Earnings Growth
Operating Cash Flow (M) -113.75
Levered Free Cash Flow (M) -132.72
Stock Valuation
PE Ratio 49.10
PEG Ratio
Price to Book value 0.78
Price to Sales 3.99
Price to Cash Flow -4.48
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android